The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial

Atherosclerosis

Volumn 233, Issue 2, 2014, Pages 707-712

  Zhao, Shui ping ^a   Yu, Bi lian ^a   Peng, Dao quan ^a   Huo, Yong ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Acute coronary syndrome; LDL cholesterol; Lipid lowering; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; C REACTIVE PROTEIN; CARDIOVASCULAR AGENT; HEPTANOIC ACID DERIVATIVE; LIPID; PYRROLE DERIVATIVE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; UNSTABLE ANGINA PECTORIS; YOUNG ADULT; BIOASSAY; BLOOD; CHINA; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COMBINATION; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR AGENTS; CHINA; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; TREATMENT OUTCOME;

EID: 84896293995     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.12.003     Document Type: Article

References (25)

1. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718.
2. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. NEngl J Med 2004, 350:1495-1504.
3. Ray K.K., Cannon C.P., McCabe C.H., et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. JAm Coll Cardiol 2005, 46:1405-1410.
4. Smith S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113:2363-2372.
5. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z., Catapano A.L., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
6. Zhao S.P., Peng D.Q., Yu B.L., et al. Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study. Am Heart J 2009, 158:509-512.e1. 10.1016/j.ahj.2009.07.030.
7. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995, 345:1274-1275.
8. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet 2002, 360:7-22.
9. Pfeffer M.A., Sacks F.M., Moyé L.A., et al. Influence of baseline lipids on effectiveness of pravastatin in the CARE trial. Cholesterol and recurrent events. JAm Coll Cardiol 1999, 33:125-130.
10. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. NEngl J Med 1998, 339:1349-1357.
11. Giraldez R.R., Giugliano R.P., Mohanavelu S., et al. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy. A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. JAm Coll Cardiol 2008, 52:914-920.
12. Lee J.H., Park S.H., Yang D.H., et al. Threshold level of low-density lipoprotein cholesterol for the short-term benefit of statin therapy in the acute phase of myocardial infarction. Clin Cardiol 2012, 35:211-218.
13. Sacks F.M., Pasternak R.C., Gibson C.M., et al. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. Lancet 1994, 344:1182-1186.
14. Lu Z., Kou W., Du B., et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008, 101:1689-1693.
15. He J., Gu D., Wu X., et al. Major causes of death among men and women in China. NEngl J Med 2005, 353:1124-1134.
16. Yang W., Xiao J., Yang Z., et al. Serum lipids and lipoproteins in Chinese men and women. Circulation 2012, 125:2212-2221.
17. Colivicchi F., Tubaro M., Santini M. Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes. Int J Cardiol 2011, 152:56-60.
18. Aliprandi-Costa B., Ranasinghe I., Chow V., et al. Management and outcomes of patients with acute coronary syndromes in Australia and New Zealand, 2000-2007. Med J Aust 2011, 195:116-121.
19. Tao S.C., Huang Z.D., Wu X.G., et al. CHD and its risk factors in the People's Republic of China. Int J Epidemiol 1989, 18:S159-S163.
20. Joint Committee for Developing Chinese guidelines on Prevention and Treatment of Dyslipidemia in Adults Chinese guidelines on prevention and treatment of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi 2007, 35:390-419.
21. Miyauchi K., Kimura T., Morimoto T., et al. Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design. Circ J 2006, 70:1624-1628.
22. Lee E., Ryan S., Birmingham B., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005, 78:330-341.
23. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. NEngl J Med 2005, 352:1425-1435.
24. Alsheikh-Ali A.A., Maddukuri P.V., Han H., et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. JAm Coll Cardiol 2007, 50:409-418.
25. Ray K.K., Cannon C.P. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. JAm Coll Cardiol 2005, 4:1425-1433.